VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

27 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

06 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

01 Feb 2023 21:51:59 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

01 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investor Conferences

22 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

17 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

09 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

05 Nov 2022 16:50:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

17 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in September 2022

07 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

10 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

06 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

04 Jun 2022 14:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

02 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

20 May 2022 16:05:00 By Nasdaq GlobeNewswire